Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
2X-121 · 1 trial · 1 indication
To evaluate the optimal dose of 2X-121 as single agent therapy at 600 mg daily compared to 800 mg daily.
| Arm | Type | Description |
|---|---|---|
| Drug: 2X-121 600 mg | EXPERIMENTAL | 2X-121 will be administered daily as 600 mg (200 mg 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle. |
| Drug: 2X-121 800 mg | EXPERIMENTAL | 2X-121 will be administered 800 mg (400 mg (2 x 200 mg) 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle. |
| Name | Type | Description |
|---|---|---|
| 2X-121 | DRUG | 2X-121 will be administered daily as 600 mg (200 mg 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle. |
Inclusion Criteria: 1. Signed informed consent form. 2. Age 18 years or older. 3. Histologically or cytologically documented epithelial ovarian, fallopian tube, or primary peritoneal tumors, with high-grade serous or endometrioid, or predominantly serous/endometrioid histology (independent of BRCA1...
Top 20 of 59 competitors
2X-121 is an investigational small molecule being studied for the treatment of recurrent, advanced ovarian cancer. It is currently in Phase 2 clinical development and is not yet approved by the FDA. The drug is being evaluated in a controlled clinical trial enrolling female patients aged 18 years and older in the United States.
2X-121 is a small molecule oncology drug. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being investigated for its anti-tumor effect in patients with recurrent, advanced ovarian cancer, but the precise mechanism of action is not publicly detailed.
2X-121 is being developed by Allarity Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ALLR. The company is conducting a Phase 2 clinical trial of 2X-121 in patients with recurrent, advanced ovarian cancer.
2X-121 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 2 trial is recruiting patients with recurrent, advanced ovarian cancer in the United States.
2X-121 is being studied in a single Phase 2 clinical trial registered as NCT03878849. The trial is titled "Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer." It is a controlled, randomized study with a target enrollment of 40 female patients aged 18 years and older.
2X-121 is the drug name used in clinical trial registrations for the investigational treatment of advanced ovarian cancer. No alternative names for 2X-121 have been publicly listed in the available clinical trial information.